Keywords : SARS-CoV-2

Pitfalls in Interpretation of SARS-CoV-2 Infection-related Neurological Complications

Seraph Shi Kei Wu; Sunny Chi Lik Au

Canadian Journal of Medicine, In Press
DOI: 10.33844/cjm.2021.60602

Coronavirus disease (COVID-19) is an ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many systematic reviews and meta-analyses discussed the correlation of COVID-19 with a different disease. Given the urgent need for data, some meta-analyses containing datasets included many manuscripts, but their providence was not clearly reported. The possible overlap between some of the studies included in the analyses is a significant issue for conducting systematic reviews during the COVID-19 pandemic.

An Overview of COVID-19 Treatment: Possible Candidates Based on Drug Repurposing and Molecular Docking

Mai Abdelgawad; Sahar Allam; Maha Abdelmonaem Shaheen; Mohamed Ali Hussein; Hoda Azmy Elkot; Aya A. Gaber; Khaled A. Marghany; Asmaa A. Abdelwahab; Rewan H. Alashrey; Hoda Y. Abdallah

Canadian Journal of Medicine, 2021, Volume 3, Issue 1, Pages 10-35
DOI: 10.33844/cjm.2021.60499

The current pandemic of COVID-19 is considered a worldwide threat to public health caused
by a novel type of coronaviridae family called SARS-CoV-2. Owing to the urge of finding a
treatment for this virulent virus, many aspects of drug development are swept aside. This
review aimed to clarify the double-edged sword of drug repurposing in COVID-19 via
summarizing the available treatment options and promising candidates for COVID-19 based
on drug repurposing preclinical studies and in-silico approach. Different drugs target SARS
CoV-2 main structures under clinical investigation; some showed limited efficacy and severe
side effects, while others can be promising solutions. Some drugs suppress the cytokine storm
and modulate immune response during viral infection, including anti-interleukin and
glucocorticoids. Antiparasitic agents are repurposed for SARS-CoV-2 infection management.
Various vaccines and monoclonal antibodies are designed against SARS-CoV-2 and are being
evaluated in different preclinical and clinical stages. However, none of them is approved yet.
Convalescent Plasma Transfusion is a promising strategy against SARS-CoV-2 infection,
where impressive results are reported in clinical trials, requiring more validation. Furthermore,
anticoagulant therapy exhibited better disease outcomes in patients admitted to the ICU.
Finally, in-silico studies suggested several potential compounds or FDA-approved drugs
targeting various viral structure subunits. In conclusion, although many clinical trials were
launched to examine potential therapies based on drug repurposing for COVID-19, there is no
definitive treatment till now. Moreover, computational approaches identified several
compounds and FDA-approved drugs with potential inhibitory effects.